Cancer patient getting treatment Emerging therapies for cancer not only promise greater survival rates, but also potentially less costs as they require far less time to do their job, according to the report. (Photo: Shutterstock)

Considering that more than a third of Americans will be diagnosed with cancer at some point in their lifetime, and injectable drugs for cancer are among the most expensive partly due to lengthy treatments, it's no surprise that cancer continues to be the costliest stop-loss claim for self-insured employers, according to the 2019 Sun Life Stop-Loss Research Report: High-cost claims and injectable drug trends.

But there's good news: emerging therapies for cancer not only promise greater survival rates, but also potentially less costs as they require far less time to do their job, according to the report.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.